Accro Bioscience(Suzhou)Limited
Total raised: $12M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.03.2025 | Series B | $12M | - |
Mentions in press and media 7
| Date | Title | Description |
| 16.03.2025 | Accropeutics: $12 Million (Series B+) Closed For Developing Therapeutics For Immune Mediated Diseases | Accropeutics, a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune-mediated diseases, announced the closing of its $12 million Series B P... |
| 15.03.2025 | Accropeutics Secures $12 Million to Propel Innovative Therapies | In the bustling world of biotechnology, Accropeutics Inc. has just made waves. The company, based in Suzhou, China, has successfully secured $12 million in Series B Plus financing. This funding round was led by Shenzhen Capital Group (SCGC)... |
| 14.03.2025 | Accropeutics Raises $12M in Series B Plus Financing | Accropeutics, a Suzhou, China-based clinical-stage biotechnology company that develops novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, raised $12M in Series B funding. The round was ... |
| 14.03.2025 | nunu.ai Raises $6m in Seed Funding | nunu.ai, a San Francisco, CA-based startup building AI agents capable of testing and playing games, raised $6m in Seed funding. The round was co-led by Tirta Ventures and a16z speedrun. The company intends to use the funds to expand operati... |
| 14.03.2025 | Accropeutics Secured $12 Million in Series B Plus Financing | Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST)... |
| 13.02.2025 | Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101 | NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated d... |
| 13.12.2024 | Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101 | Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China AC-101 demonstrated a favorable safety and PK... |